Mind Cure Health Inc. MCURF Archives - Page 2 of 5

TuesdayNov 30, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022 The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022 Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022 As a member of the Digital Therapeutics Alliance, Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) delivers digital therapeutics (“DTx”) that are evidence-based interventions driven by high-quality software to prevent, manage, and treat medical disorders…

MondayNov 15, 2021 12:34 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Featured in Equity Research Report

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs and clinical development, including synthetic ibogaine, for which it is planning a preclinical study with its research partner to initially conduct cardiac and neurological screens with data and potentially move into behavioral studies. In addition, the company plans to schedule a pre-IND meeting for its…

FridayNov 12, 2021 3:08 pm

QualityStocksNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently signed a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing and delivering psychedelic medicine to treat addiction. “Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for alcohol use disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM,” reads a recent article. In addition to distributing its partners’ protocols, MINDCURE will also be distributing its own protocols through iSTRYM.…

ThursdayNov 04, 2021 1:22 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Provides Studies, Clinical Trials Update

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has released an update on strategic initiatives related to its MINDCURE Research and MINDCURE Technology divisions. According to the company, its synthetic ibogaine efforts, which were announced in March 2021, include the application for two patents and the initiation of production of Good Laboratory Practice (“GLP”) ibogaine leading to the production of Good Manufacturing Practice (“GMP”) ibogaine. The company is on schedule to provide GLP supply to research partners by Q2 2022. The company is in the process of preparing to ship…

ThursdayNov 04, 2021 12:12 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

The distribution component unlocks a new revenue source for the company, helping drive future growth MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the…

ThursdayOct 28, 2021 12:36 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has signed a nonbinding letter of intent with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF). Awakn is a biotechnology company with clinical operations focused on researching, developing and delivering psychedelic medicine to better treat addiction. According to the agreement, MINDCURE will distribute Awakn’s ketamine-assisted psychotherapy for alcohol use disorder protocol via its digital therapeutics platform, iSTRYM. Distribution began in August when MINDCURE released the minimum viable product version of iSTRYM into partner clinics across North America with full commercial deployment to all partner clinics slated for…

WednesdayOct 27, 2021 10:21 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Sponsor, Participate In Upcoming Events

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, announced its participation in two upcoming November events. The company will be a silver sponsor of Wonderland Miami, the largest in-person conference focused on the psychedelic medicine industry. At Wonderland, MINDCURE president and CEO Kelsey Ramsden will participate in several panel discussions scheduled during the in-person, two-day event. Slated for Nov. 8–9, 2021, Wonderland Miami is presented by Microdose Psychedelic Insights, a portfolio company of Origin Therapeutics. In addition, MINDCURE is also scheduled to participate in next month’s International Summit on Psychedelic Therapies for…

FridayOct 22, 2021 12:34 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Identifies Market Gap, Launches ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. The study comprises some of the world’s leading researchers in female sexual desire and psychedelics. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from the…

FridayOct 15, 2021 11:37 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Focusing on What It Does Best

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently released its financial results for the twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. “The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function. With the company’s renewed focus on its digital technology and research development activities, MINDCURE announced in August that it had discontinued the development of its nootropics line of…

ThursdayOct 07, 2021 12:49 pm

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) to Present at KCSA Psychedelics Virtual Investor Conference

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced that its president and CEO Kelsey Ramsden will present virtually at the KCSA Psychedelics Investor Conference, which will be held Oct. 13-14, 2021, at VirtualInvestorConferences.com. Ramsden’s presentation is scheduled to begin at 12 p.m. ET on Oct. 13, 2021. The live, interactive online event is designed to enable investors to ask presenting companies questions in real-time. Interested parties should visit https://ibn.fm/cKm11 to register for and access the event. It is recommended that investors pre-register and run the online system check to expedite…

Site Search

Company Search

Tag: Mind Cure Health Inc. MCURF